Open AccessFEATURES OF THE PHENOTYPE OF REGULATORY T CELLS IN EARLY AND ADVANCED RHEUMATOID ARTHRITIS
Author(s) -
А. С. Авдеева,
Ю. П. Рубцов,
Т. В. Попкова,
Daniyar T. Dyikanov,
А. П. Алексанкин,
Е. Л. Насонов
Publication year - 2018
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 9
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.14412/1995-4484-2018-423-428
Subject(s) - foxp3 , cd154 , il 2 receptor , interleukin 7 receptor , cd3 , cd8 , cd19 , flow cytometry , medicine , immunology , regulatory t cell , microbiology and biotechnology , t cell , biology , immune system , cd40 , cytotoxic t cell , in vitro , biochemistry
Objective: to analyze the levels of CD3+, CD3+CD4+, CD3+CD8+, and CD3-CD56+ T lymphocytes, FoxP3+ regulatory T cells (T reg ), and CD19+ B lymphocytes in patients with early and advanced rheumatoid arthritis (RA). Subjects and methods. The investigation enrolled 45 patients previously untreated with methotrexate (MTX-naive) who had early RA and 15 patients who had advanced RA. Immunofluorescence staining and multicolor flow cytometry assays were used to estimate the percentage and absolute (abs) counts of CD3+, CD3+CD4+, CD3+CD8+, CD3-CD16+CD56+, CD19+, T reg (FoxP3+CD25+; surface CD152+; intracellular CD152+; FoxP3+CD127; CD25+CD127-; FoxP3+ICOS+; FoxP3+CD154+; and FoxP3+CD274+. Results and discussion. The patients with early RA were found to have a lower percentage of FoxP3+CD25+ cells and lower percentages and abs counts of FoxP3+ ICOS+ cells, FoxP3+CD154+ cells, and FoxP3+ CD274+ T cells than healthy donors (p<0.05 in all cases). Conclusion. Patients with RA (with the early or advanced stage of the disease) show a decrease in both the counts and functional activity of T reg . The patients with advanced RA compared with those with early RA showed an increase in CD4+ lymphocyte counts and a decrease in CD25+CD127- cell levels, which suggests that there are more pronounced impairments in T reg homeostasis in advanced RA.